{"id":"drug-eluting-embolic-bead","safety":{"commonSideEffects":[{"rate":null,"effect":"Post-embolization syndrome (fever, pain, nausea)"},{"rate":null,"effect":"Hepatic dysfunction"},{"rate":null,"effect":"Vascular complications"},{"rate":null,"effect":"Systemic chemotherapy toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These beads are injected into the arterial blood supply feeding a tumor, where they lodge in small vessels and release chemotherapy drugs locally over time while simultaneously causing embolization (vessel blockage). This dual mechanism—local drug delivery combined with ischemia—maximizes tumor exposure to cytotoxic agents while minimizing systemic toxicity. The approach is particularly suited for hepatocellular carcinoma and other hypervascular tumors.","oneSentence":"Drug-eluting embolic beads deliver chemotherapy directly to tumors while occluding blood vessels to starve them of oxygen and nutrients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:05.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (transarterial chemoembolization)"},{"name":"Hypervascular tumors amenable to arterial delivery"}]},"trialDetails":[{"nctId":"NCT06555003","phase":"PHASE3","title":"DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","status":"RECRUITING","sponsor":"Tehran University of Medical Sciences","startDate":"2025-01-20","conditions":"Liver Neoplasm, Colorectal Cancer Metastatic","enrollment":116},{"nctId":"NCT04297280","phase":"PHASE2","title":"TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-04-29","conditions":"Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT06353126","phase":"PHASE4","title":"DEB-TACE Prior to Liver Transplantation in the Treatment of HCC","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-10-16","conditions":"Liver Cancer","enrollment":40},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT05093920","phase":"EARLY_PHASE1","title":"Role of DEB-TACE Versus c-TACE in Treatment of HCC","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-01-01","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT03969576","phase":"NA","title":"Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-09-15","conditions":"Hepatocellular Carcinoma","enrollment":344},{"nctId":"NCT02729506","phase":"PHASE4","title":"Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2016-01","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT00877071","phase":"PHASE2","title":"LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-11","conditions":"Hepatocellular Carcinoma","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":363,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Irinotecan-loaded drug-eluting beads (DEBIRI) plus systemic chemotherapy +/- targeted therapy"],"phase":"phase_3","status":"active","brandName":"Drug-Eluting Embolic Bead","genericName":"Drug-Eluting Embolic Bead","companyName":"Tehran University of Medical Sciences","companyId":"tehran-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Drug-eluting embolic beads deliver chemotherapy directly to tumors while occluding blood vessels to starve them of oxygen and nutrients. Used for Hepatocellular carcinoma (transarterial chemoembolization), Hypervascular tumors amenable to arterial delivery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}